OncoMatch/Clinical Trials/NCT06440954
Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases
Is NCT06440954 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Intrathecal pemetrexed for non-small cell lung cancer.
Treatment: Intrathecal pemetrexed — This is a prospective interventional study clinical study to investigate the efficacy and resistance mechanisms of intrathecal pemetrexed in patients with driver gene mutations advanced NSCLC with leptomeningeal metastases.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK fusion
Required: BRAF mutation
Required: EGFR mutation
Required: KRAS mutation
Required: NTRK1 fusion
Required: NTRK2 fusion
Required: NTRK3 fusion
Required: RET fusion
Required: ROS1 fusion
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: tyrosine kinase inhibitor
leptomeningeal metastasis after TKI resistant
Cannot have received: intrathecal pemetrexed
Previously received intrathecal pemetrexed therapy for locally advanced or metastatic disease.
Lab requirements
Blood counts
adequate bone marrow hematopoiesis
Kidney function
adequate organ function
Liver function
adequate organ function
Adequate bone marrow hematopoiesis and organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify